A(1-7) Reduces Pathologies Associated with SLE in MRL-lpr Mice

The study demonstrated that daily treatment with angiotensin (1-7) [A(1-7)] for 6 weeks significantly reduced various pathologies associated with Systemic Lupus Erythematosus (SLE) in MRL-lpr mice. Specifically, A(1-7) treatment lowered proteinuria levels, reduced glomerular pathologies, decreased the size of inguinal and axillary lymph nodes, and lowered anti-dsDNA IgG levels compared to saline-treated MRL-lpr mice. Additionally, A(1-7) treatment mitigated the severity of cutaneous pathologies, including inflammation and hair loss. These findings suggested that Mas agonists like A(1-7) could be promising candidates for future SLE therapies.